The influenza virus lysis vaccine from the Shanghai Institute of Biological Products, a subsidiary of Sinopharm Group China Biology, has successfully obtained a batch issuance certificate, marking the official launch of the new season of the Chinese biological influenza virus lysis vaccine on the market, which will provide strong support for influenza prevention and control in 2026-2027. The Chinese biological influenza virus lysis vaccine was developed using the 2026-2027 northern hemisphere influenza vaccine strain recommended by the World Health Organization.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.